BR9712168A - Processes for the treatment or prevention of a cardiovascular disorder in a human, treatment or prevention of stroke, cerebral thrombosis or memory loss due to stroke, treatment or prevention of fatty liver conditions in a human , improvement or maintenance of cardiovascular health, treatment or prevention of diabetes in a human and reduction of serum cholesterol and triglyceride levels, nutritional or pharmaceutical composition, medication, and red yeast fermentation product suitable for release oral in humans. - Google Patents

Processes for the treatment or prevention of a cardiovascular disorder in a human, treatment or prevention of stroke, cerebral thrombosis or memory loss due to stroke, treatment or prevention of fatty liver conditions in a human , improvement or maintenance of cardiovascular health, treatment or prevention of diabetes in a human and reduction of serum cholesterol and triglyceride levels, nutritional or pharmaceutical composition, medication, and red yeast fermentation product suitable for release oral in humans.

Info

Publication number
BR9712168A
BR9712168A BR9712168-1A BR9712168A BR9712168A BR 9712168 A BR9712168 A BR 9712168A BR 9712168 A BR9712168 A BR 9712168A BR 9712168 A BR9712168 A BR 9712168A
Authority
BR
Brazil
Prior art keywords
treatment
prevention
human
stroke
processes
Prior art date
Application number
BR9712168-1A
Other languages
Portuguese (pt)
Inventor
Mao L Zhang
Chi X Pong
Michael N Chang
Original Assignee
Pharmanex Inc
Univ Beijing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmanex Inc, Univ Beijing filed Critical Pharmanex Inc
Publication of BR9712168A publication Critical patent/BR9712168A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungal isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)

Abstract

"PROCESSOS DE TRATAMENTO OU DE PREVENçãO DE UM DISTúRBIO CARDIVASCULAR EM UM HUMANO, DE TRATAMENTO OU DE PREVENçãO DE ACIDENTE VASCULAR CEREBRAL, TROMBOSE CEREBRAL OU DE PERDA DE MEMóRIA DEVIDO AO ACIDENTE VASCULAR CEREBRAL, DE TRATAMENTO OU DE PREVENçãO DE CONDIçõES DE FìGADO GORDUROSO EM UM HUMANO, DE MELHORIA OU DE MANUTENçãO DA SAúDE CARDIOVASCULAR, DE TRATAMENTO OU DE PREVENçãO DE DIABETES EM UM HUMANO, DE TRATAMENTO OU DE PREVENçãO DE OBESIDADE EM UM HUMANO E DE REDUçãO DOS NìVEIS DE COLESTEROL E DE TRIGLICERìDEO DO SORO, COMPOSIçãO NUTRICIONAL OU FARMACêUTICA, MEDICAMENTO, E, PRODUTO DE FERMENTAçãO DE LEVEDURA VERMELHA ADEQUADO PARA LIBERAçãO ORAL EM HUMANOS". Processos e composições são descritos os quais compreendem produtos de fermentação de levedura vermelha, que podem ser utilizados como suplementos dietéticos naturais e/ou medicamentos para o tratamento ou a prevenção de hiperlipidemia e distúrbios e sintomas associados, tais como doenças cardiovasculares, doenças cerebrovasculares, diabetes, hipertensão, obesidade, respiração astênica, dor de cabeça crónica, dor e aperto torácicos, distensão e tumefação de membro, perda de apetite e excesso de expectoração. Os processos e composições são efetivos no abaixamento dos níveis séricos tanto de colesterol quanto de triglicerídeo em humanos, e podem ser usados para manter saúde cardiovascular. A invenção também engloba cepas específicas de Monascus que rendem produtos de fermentação com as atividades biológicas desejadas."PROCESSES FOR THE TREATMENT OR PREVENTION OF A CARDIVASCULAR DISORDER IN A HUMAN, TREATMENT OR PREVENTION OF CEREBRAL ACCIDENT, CEREBRAL THROMBOSIS OR LOSS OF MEMORY DUE TO CEREBRAL VASCULAR ACCIDENT, TREATMENT OR TREATMENT. HUMAN, IMPROVEMENT OR MAINTENANCE OF CARDIOVASCULAR HEALTH, TREATMENT OR PREVENTION OF DIABETES IN A HUMAN, TREATMENT OR PREVENTION OF OBESITY IN A HUMAN AND REDUCING THE CHOLESTEROL AND TRUTHICERIC NUTRITION LEVELS, OR NUTRITION, ORGANIC NUTRITION MEDICINE, AND, RED YEAST FERMENTATION PRODUCT SUITABLE FOR ORAL RELEASE IN HUMANS ". Processes and compositions are described which comprise red yeast fermentation products, which can be used as natural dietary supplements and / or medications for the treatment or prevention of hyperlipidemia and associated disorders and symptoms, such as cardiovascular diseases, cerebrovascular diseases, diabetes , hypertension, obesity, asthenic breathing, chronic headache, chest pain and tightness, distension and swelling of the limb, loss of appetite and excess sputum. The processes and compositions are effective in lowering both serum cholesterol and triglyceride levels in humans, and can be used to maintain cardiovascular health. The invention also encompasses specific strains of Monascus that yield fermentation products with the desired biological activities.

BR9712168-1A 1996-09-30 1997-09-29 Processes for the treatment or prevention of a cardiovascular disorder in a human, treatment or prevention of stroke, cerebral thrombosis or memory loss due to stroke, treatment or prevention of fatty liver conditions in a human , improvement or maintenance of cardiovascular health, treatment or prevention of diabetes in a human and reduction of serum cholesterol and triglyceride levels, nutritional or pharmaceutical composition, medication, and red yeast fermentation product suitable for release oral in humans. BR9712168A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72054896A 1996-09-30 1996-09-30
PCT/US1997/017574 WO1998014177A1 (en) 1996-09-30 1997-09-29 Methods and compositions employing red yeast fermentation products

Publications (1)

Publication Number Publication Date
BR9712168A true BR9712168A (en) 2000-01-18

Family

ID=24894390

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712168-1A BR9712168A (en) 1996-09-30 1997-09-29 Processes for the treatment or prevention of a cardiovascular disorder in a human, treatment or prevention of stroke, cerebral thrombosis or memory loss due to stroke, treatment or prevention of fatty liver conditions in a human , improvement or maintenance of cardiovascular health, treatment or prevention of diabetes in a human and reduction of serum cholesterol and triglyceride levels, nutritional or pharmaceutical composition, medication, and red yeast fermentation product suitable for release oral in humans.

Country Status (9)

Country Link
EP (1) EP0932395A1 (en)
JP (1) JP2001501621A (en)
KR (1) KR20000048765A (en)
AU (1) AU4658797A (en)
BR (1) BR9712168A (en)
CA (1) CA2267340A1 (en)
HU (1) HUP9904650A2 (en)
IL (1) IL129216A0 (en)
WO (1) WO1998014177A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436406B1 (en) 2000-06-15 2002-08-20 A. Glenn Braswell Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis
KR100426880B1 (en) * 2002-02-04 2004-04-13 학교법인 영광학원 method for production of red pigment in meju by Monascus pilosus
KR20020093147A (en) * 2002-05-30 2002-12-13 지니스생명공학 주식회사 Preventive and Dietary Supplement for adult chronic disease
KR20060028426A (en) * 2003-06-24 2006-03-29 오츠카 세이야쿠 가부시키가이샤 Composition for lowering serum uric acid level
US20100119600A1 (en) * 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
TW201038205A (en) * 2009-04-29 2010-11-01 Sunway Biotech Co Ltd The compositions of Monascus fermented products with a function that reduces body fatness formation and the method for manufacturing the same
JP2010273569A (en) * 2009-05-26 2010-12-09 Wasaburo Sato Drink and supplement each having metabolic syndrome-improving action
JP5912361B2 (en) * 2011-09-16 2016-04-27 晨暉生物科技股▲分▼有限公司 Mixture capable of lowering blood lipid and raising HDL cholesterol and method for producing the same
US10889612B2 (en) 2011-12-26 2021-01-12 Beijing Peking University Wbl Biotech Co., Ltd. Sterol derivatives and preparation method and uses thereof
CN113171316B (en) * 2021-04-23 2022-06-14 科丝美诗(中国)化妆品有限公司 Cosmetic for repairing and relieving skin irritation and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56150037A (en) * 1980-04-22 1981-11-20 Sankyo Co Ltd Hydronaphthalene compound
JP3168298B2 (en) * 1993-02-05 2001-05-21 有限会社フジ・バイオ研究所 Production method of spirit drink using red yeast rice

Also Published As

Publication number Publication date
KR20000048765A (en) 2000-07-25
HUP9904650A2 (en) 2000-05-28
EP0932395A1 (en) 1999-08-04
JP2001501621A (en) 2001-02-06
IL129216A0 (en) 2000-02-17
AU4658797A (en) 1998-04-24
WO1998014177A1 (en) 1998-04-09
CA2267340A1 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
EP1044009B8 (en) Methods and compositions employing red rice fermentation products
US5840715A (en) Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US6136795A (en) Dietary regimen of nutritional supplements for relief of symptoms of arthritis
BR0214838A (en) Composition for promoting bone growth and maintaining bone health
EP1604677A1 (en) Composition having antioxidant, anti-inflammatory, and immunostimulant actions
BR9712168A (en) Processes for the treatment or prevention of a cardiovascular disorder in a human, treatment or prevention of stroke, cerebral thrombosis or memory loss due to stroke, treatment or prevention of fatty liver conditions in a human , improvement or maintenance of cardiovascular health, treatment or prevention of diabetes in a human and reduction of serum cholesterol and triglyceride levels, nutritional or pharmaceutical composition, medication, and red yeast fermentation product suitable for release oral in humans.
NZ335086A (en) Bacillus thuringiensis pesticidal toxins and nucleotide sequences which encode these toxins
Mali et al. Overview of nutraceuticals
CA2240165A1 (en) Dietary regimen of nutritional supplements for relief of symptoms of arthritis
WO2008100130A2 (en) Composition containing kadok extract and collagen
CN105942490A (en) Compound enzyme composition for preventing and curing hyperlipidemia, hyperglycemia, and hypertension
Obaid The medical uses of Gum Acacia-Gum Arabic (GA) in human
KR20170139780A (en) The composition of containing musk rat that can provide the healthy blood vessel
EP3381457B1 (en) Physiologically active composition
DE202008015430U1 (en) Composition for the treatment of indigestion
CN1195529A (en) Drug for curing traumatic injuries and its preparing method
RU2826972C1 (en) Use of fermented milk products fermented with probiotic strains of bacteria bacillus subtilis tnp-3 and bacillus subtilis tnp-5 in treating patients with pulmonary tuberculosis
WO2021124912A1 (en) Composition for promoting chondroitin sulfate synthesis
CN112617206A (en) Composite probiotics for reducing inflammatory cytokines and regulating immune function and application thereof
Suryawanshi et al. REVIEW ON: NUTRACEUTICALS AND ITS IMPACT ON HEALTHCARE
KR101866065B1 (en) Preparation method of plant origin sulfur rich composition and vinegar drink application
Pizzorno Jr Natural medicine approach to treating osteoarthritis
CN116616448A (en) Vitamin C tablet containing organic selenium and production process thereof
Al Nuaimi et al. Potential Effects of Resveratrol on Obesity Markers of Iraqi Women
CN1094960A (en) Puffed fish medicine and production method thereof

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A , 5A , 6A , 7A E 8A ANUIDADES.

B15K Others concerning applications: alteration of classification

Ipc: C12R 1/645 (2006.01), A23L 33/105 (2016.0